Infantile cerebral palsy
Conditions
Interventions
The physiotherapeutic treatment will be carried out after 15 minutes of the application of Ziclague® (phytomedicine from Essential oil of Alpinia zerumbet - EOAz), time necessary for the absorption of
Biological/vaccine
E02.779
Sponsors
Universidade Tiradentes
Universidade Tiradentes
Eligibility
Age
1 Years to 12 Years
Inclusion criteria
Inclusion criteria: Patients with Spastic Cerebral Palsy; Diparetic or tetraparetic Commitment; Classified by the Modified Ashworth Scale between One and Three grades; Aged between One and Twelve years old.
Exclusion criteria
Exclusion criteria: Children with Hypotension, the medication Ziclague is contraindicated (according to the package insert) to people with blood pressure lower than 100 / 60mmHg; Heart disease, avoid applying medication that has not yet been tested in children with Cerebral Palsy who are cardiac patients; Excessive irritability, hyperactivity, involuntary movements, other syndromes or neurological disorders in addition to cerebral palsy, these kinetic disorders will interfere in the performance of the exercises proposed in the treatment of the study, which may generate false results; That have not been subjected to the application of botulinum toxin, the application of botulinum toxin will promote relaxation by decreasing acetylcholine that directly interferes with the pharmacodynamics of the Ziclague® that presents a therapeutic target to the type L calcium channels and releases the action of acetylcholine in the muscles; Surgery on the spine or hip in the last 6 months, these surgeries in this period contraindicate or induce an unviable physical condition for trunk activities or orthostatic activities that make the protocol proposed by the present project unfeasible; Participants who do not adhere correctly to the treatment, ensuring participation in the treatment sessions and following the guidelines prescribed by the researchers; Who have any health problems that interfere with their motor condition; Who develop an allergic reaction to the drug Ziclague®, after starting treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To influence the muscle hypertonia in children with cerebral palsy after Ziclague® application associated to kinesiotherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| To reduce the severity level of the motor functions, using the Gross Motor Function Classification System (GMFCS);To classify the functionality of the body functions and structures and the tasks performances before and after the treatment, through International Classification of Functionality, Incapacity and Health (ICF);To modulate the muscle hypertonia reducing the score grade of Modified Ashworth Scale;To identify trajectories, velocity, angles, and movement time, discrepancies in movement patterns and cinematic performance through CvMob 3.5 software;To evaluate the postural control through level of trunk control before and after treatment with Segmental Assessment of Trunk Control (SATCo) | — |
Countries
Brazil
Contacts
Public ContactEdna Cândido
Universidade Tiradentes
Outcome results
None listed